Boundless Bio’s freshman year on the public markets hasn’t been easy, with “modest” layoffs in the summer followed by news ...

Apimostinel has a similar mode of action to ketamine and derivatives like Johnson & Johnson's Spravato (esketamine) – ...

Ajna BioSciences and British American Tobacco, yielded positive results from a phase-1 dose trial of AJA001, its cannabis-based drug candidate to treat symptoms of autism spectrum disorder ・Results ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

In LAVA-1207’s absence, Lava will now be bumping up LAVA-1266, which is due to enter the clinic before the end of the year.

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.